Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/7855808 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565758894276608 |
|---|---|
| author | Alana MacDonald T.-C. Wu Chien-Fu Hung |
| author_facet | Alana MacDonald T.-C. Wu Chien-Fu Hung |
| author_sort | Alana MacDonald |
| collection | DOAJ |
| description | Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8+ T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods. |
| format | Article |
| id | doaj-art-fb172ce1ca654f948f000f3fe9370909 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-fb172ce1ca654f948f000f3fe93709092025-02-03T01:06:48ZengWileyJournal of Immunology Research2314-71562021-01-01202110.1155/2021/7855808Interleukin 2-Based Fusion Proteins for the Treatment of CancerAlana MacDonald0T.-C. Wu1Chien-Fu Hung2Department of PathologyDepartment of PathologyDepartment of PathologyInterleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8+ T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods.http://dx.doi.org/10.1155/2021/7855808 |
| spellingShingle | Alana MacDonald T.-C. Wu Chien-Fu Hung Interleukin 2-Based Fusion Proteins for the Treatment of Cancer Journal of Immunology Research |
| title | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
| title_full | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
| title_fullStr | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
| title_full_unstemmed | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
| title_short | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
| title_sort | interleukin 2 based fusion proteins for the treatment of cancer |
| url | http://dx.doi.org/10.1155/2021/7855808 |
| work_keys_str_mv | AT alanamacdonald interleukin2basedfusionproteinsforthetreatmentofcancer AT tcwu interleukin2basedfusionproteinsforthetreatmentofcancer AT chienfuhung interleukin2basedfusionproteinsforthetreatmentofcancer |